细胞分型、分子亚型及p53基因异常在弥漫大B细胞淋巴瘤预后中的研究进展  

Progress of cell phenotypes and molecular subtypes as well as p53 gene abnormalities in the prognosis of diffuse large B-cell lymphoma

作　　者：古佳 贺建霞 Gu Jia;He Jianxia(Graduate School,Shanxi Medical University,Taiyuan 030001,China;Department of Hematology,People's Hospital Affiliated to Shanxi Medical University,Taiyuan 030012,China)

机构地区：[1]山西医科大学研究生院,太原030001 [2]山西医科大学附属人民医院血液科,太原030012

出　　处：《肿瘤研究与临床》2021年第10期797-800,共4页Cancer Research and Clinic

基　　金：山西省应用基础研究项目(201901D111435)。

摘　　要：弥漫大B细胞淋巴瘤(DLBCL)是一组异质性疾病, 进一步分型对预后分层有着重要价值。近年来, 一些预后较差的亚型, 如"双打击"淋巴瘤或"双表达"淋巴瘤逐渐被认识。此外新的分子学分型为DLBCL的精准诊断及预后分层带来新视角。p53基因突变和缺失是DLBCL传统意义上的高危因素, 但随着二代测序等技术的应用, 更精确的基因突变或缺失对预后的影响及其在新的细胞分子亚型中的预后价值尚需进一步证实。现就细胞分型、分子学分型及p53基因异常在DLBCL预后的研究进展进行综述。Diffuse large B-cell lymphoma(DLBCL)is a group of heterogeneous diseases,and further classification is of great value for prognostic stratification.In recent years,some subtypes with poor prognosis have been recognized,such as"double-hit"lymphoma or"double-expressing"lymphoma.In addition,the new molecular classification provides a new perspective for the accurate diagnosis and prognosis stratification of DLBCL.The mutation and deletion of p53 gene are high risk factors in the traditional sense of DLBCL,while with the application of the next generation sequencing and other technologies,the influence of more accurate gene mutation or deletion on prognosis and its prognostic value in new cell molecular subtypes still need to be further confirmed.This paper reviews the progress of cell phenotypes and molecular subtypes as well as p53 gene abnormalities in the prognosis of DLBCL.

关 键 词：淋巴瘤 大B-细胞 弥漫性 基因 P53 基因型 分子生物学 预后 

分 类 号：R733.1[医药卫生—肿瘤]